Harrow, Inc. (HROW)

Over the past six months, Harrow's stock has experienced significant activity, increasing by 55.98% but falling -20.58% in the last month and -29.05% over the last year as of October 2025. Several firms reiterated "Buy" recommendations, with target prices ranging from $63.00 to $76.00. Harrow agreed to acquire Melt Pharmaceuticals in late September 2025 and commenced a private offering of $250 million of senior notes. In June 2025, Harrow acquired exclusive U.S. commercial rights for BYQLOVI, and in July 2025, acquired U.S. rights to Samsung Bioepis' ophthalmology biosimilars pipeline. Harrow reported record revenues of $66.8 million for Q4 2024 and $199.6 million for the full year, but Q1 2025 revenues fell short of expectations, with a net loss of $17.8 million. Q3 2024 results showed revenue growth, but high SG&A costs led to a net loss, causing the stock to drop. The successful launch and growth of VEVYE and IHEEZO have been significant drivers.

Harrow, Inc.'s business experiences predictable seasonal patterns, with the first quarter typically being the weakest financially due to factors such as prior-quarter stocking by customers, surgical scheduling patterns, and the resetting of annual insurance deductibles. The company anticipates revenues to accelerate quarter-over-quarter, with stronger performance expected in the second half of the year.

Harrow, Inc. is an ophthalmology-focused pharmaceutical company specializing in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company is dedicated to providing safe, effective, accessible, and affordable medications to enhance patient compliance and improve clinical outcomes in eye care. Its product portfolio includes a wide range of FDA-approved prescription and non-prescription pharmaceuticals for various eye conditions. Key products include ImprimisRx, IHEEZO, VEVYE, TRIESENCE, IOPIDINE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, MAXITROL, MAXIDEX, TOBRADEX ST, VERKAZIA, NEVANAC, and FRESHKOTE preservative-free (PF) lubricant eye drops. The company also has a pipeline of biosimilars, including BYOOVIZ and OPUVIZ.

Harrow, Inc. primarily operates across the United States and is headquartered in Nashville, Tennessee.

Harrow, Inc. generally maintains a positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy". Analysts have set optimistic price targets, indicating confidence in the company's future growth potential. Harrow is recognized for its innovation, affordability initiatives, and entrepreneurial culture in the ophthalmic pharmaceutical industry. Financial performance challenges, such as Q3 2024 earnings miss and persistent net losses due to high SG&A costs, have led to stock drops, but this primarily reflects financial performance challenges rather than a direct negative impact on its product or ethical reputation.

A significant portion of Harrow, Inc.'s stock is held by institutional investors, ranging from 46% to 72.76%. Major institutional owners include Opaleye Management Inc., BlackRock, Inc., Private Capital Management, LLC, Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Braidwell Lp, Geode Capital Management, Llc, IWM - iShares Russell 2000 ETF, State Street Corp, and Citadel Advisors Llc. Insiders hold between 13.67% and 15% of the stock. Mark L. Baum, the CEO, is a major individual shareholder, owning 51.95% of the company's shares. Robert J. Kammer is also a significant insider owner.